REVIEW PAPER
Use of statistical data concerning hospital morbidity in epidemiological studies on rare rheumatic diseases
| 1 | Department of Social Medicine and Public Health, Medical University of Warsaw, Poland |
| 2 | National Institute of Public Health – National Institute of Hygiene, Warsaw, Poland |
| 3 | Witold Chodźko Institute of Rural Health in Lublin, Poland |
CORRESPONDING AUTHOR
Piotr Zbigniew Tyszko
Witold Chodźko Institute of Rural Health in Lublin, Poland, ul. Oczki 3, 02-007 Warszawa, Polska
Witold Chodźko Institute of Rural Health in Lublin, Poland, ul. Oczki 3, 02-007 Warszawa, Polska
Med Og Nauk Zdr. 2018;24(3):153–157
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Data validity constitutes a fundamental problem in epidemiology. An accurate estimate of the occurrence of a rare disease may require a large population study. In the case of rare diseases, all available data resources are used to estimate the occurrence rate, including statistical data concerning hospital morbidity. For life-threatening systemic vasculitides an analysis of its epidemiology is of particular importance.
Objective:
The main aim of the study was to present the possibilities for the use of data from hospital databases in an analysis of the epidemiology of rare diseases, using the example of particular systemic vasculitides.
Results:
The study shows the results of analyses performed on a population-based administrative data set concerning systemic vasculitides taken from the national hospital morbidity database prepared by the Polish National Institute of Public Health in 2004–2013. The study also discusses the main advantages and limitations of the adapted methodology. Furthermore, it proves that data from hospital databases can be used for analyzing disease incidence and prevalence, gender and territorial distribution, analysis of hospital mortality (fatality) rates, and trends in long-term observations.
Conclusions:
An analysis of the epidemiology of rare rheumatic diseases can contribute to a better understanding of their specificity, which can be useful in everyday clinical practice.
Data validity constitutes a fundamental problem in epidemiology. An accurate estimate of the occurrence of a rare disease may require a large population study. In the case of rare diseases, all available data resources are used to estimate the occurrence rate, including statistical data concerning hospital morbidity. For life-threatening systemic vasculitides an analysis of its epidemiology is of particular importance.
Objective:
The main aim of the study was to present the possibilities for the use of data from hospital databases in an analysis of the epidemiology of rare diseases, using the example of particular systemic vasculitides.
Results:
The study shows the results of analyses performed on a population-based administrative data set concerning systemic vasculitides taken from the national hospital morbidity database prepared by the Polish National Institute of Public Health in 2004–2013. The study also discusses the main advantages and limitations of the adapted methodology. Furthermore, it proves that data from hospital databases can be used for analyzing disease incidence and prevalence, gender and territorial distribution, analysis of hospital mortality (fatality) rates, and trends in long-term observations.
Conclusions:
An analysis of the epidemiology of rare rheumatic diseases can contribute to a better understanding of their specificity, which can be useful in everyday clinical practice.
REFERENCES (29)
1.
Backgroud Paper 6.19. RareDiseases. Update on 2004 Background Paper. PriorityMedicines for Europe and the World "A Public Health Approach to Innovation". 12 March 2013. www.who.int/medicines/areas/pr... (access: 2018.05.17).
2.
FAQs About Rare Diseases. Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. 2018.05.17).
https://rarediseases.info.nih.... (access: 2018.05.17).
3.
EURORDIS Rare Diseases Europe. EURORDIS’ Position Paper: Why Reserch on Rare Diseases. Oct. 2010. https://www.eurordis.org/sites... (access: 2018.02.24).
4.
COM (2008) 679 Communication from the Commission to the European Parliament, the Council the Economic and Social Committee and the Committee of the Regions on RDs: Europe’s challenges. https://eur-lex.europa.eu/lega... (access: 2018.02.24).
5.
10 things you should know about rheumatic diseases. https://www.eular.org/myUpload... (access: 2018.05.15).
6.
Pobrotyn P, Susło R, Witczak I, Milczanowski P, Drobnik J. Differences in selected medical care parameters in rheumatic disease ward patients of different ages of life. Reumatologia 2016; 54(2): 54-60.
7.
WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision, http://www.who.int/classificat....
(access: 2018.05.17).
8.
Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010 Jan; 29(6): 483–8.
9.
Ji J, Dimitrijevic I, Sundquist J, Sundquist K, Zöller B. Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden. Scand J Rheumatol. 2017 Nov; 46(6): 484–9.
10.
Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study. Int J Cardiol. 2017; 15;235:100–4.
11.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004 Dec; 114(6): 1708–33.
12.
Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M. Incidence of Wegener’s granulomatosis in Finland 1981-2000. Clin Exp Rheumatol. 2008 Jun; 26(3 Suppl 49): S81-85.
13.
Bernatsky S, Lix L, Hanly JG, Hudson M, Badley E, Peschken C, et al. Surveillance of systemic autoimmune rheumatic diseases using administrative data. Rheumatol Int. 2011 Apr; 31(4): 549–54.
14.
Bernatsky S, Joseph L, Pineau CA, Bélisle P, Boivin JF, Banerjee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009 Jul; 68(7): 1192–6.
15.
Foocharoen C, Thavornpitak Y, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Admission rate and characteristics of hospitalized systemic connective tissue disorders: analysis from a nationwide Thailand healthcare database. Int J Rheum Dis. 2013 Feb; 16(1): 41–6.
16.
Ward MM. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum. 2004 Apr; 50(4): 112.
17.
WHO Regional Committee for Europe Sixty-second Session. The European Action Plan for Strengthening Public Health Capacities and Services. EUR/RC62/12 Rev.+EUR/RC62/Conf.Doc./6 Rev.2. 24 August 2012.
http://www.euro.who.int/en/hea... (access: 2015.05.15).
18.
Rare Diseases Registers in Europe. Orphanet Report Series. Rare Diseases collection. May 2017. http://www.orpha.net/orphacom/... (access: 2018.05.15).
19.
Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order). Orphanet Report Series. Rare Diseases collection. January 2018. https://www.orpha.net/orphacom... (access: 2018.05.15).
20.
Orphanet. The portal for rare diseases and orphan drugs. Orphanet Report Series / Procedures. https://www.orpha.net/consor/c... (access: 2018.05.15).Orphadata.Welcome to Orphadata. http://www.orphadata.org/cgi-b...# (access: 2018.05.15).
22.
Act of 29 Jun 1995 on public statistics. (Journal of Laws of 1995 no. 88, item 439, as amended.
23.
National Institute of Public Health – National Institute of Hygiene. Department -Centre for Monitoring and Analyses of Population Health Status and Health Care System. Resulttables for General Hospital Disease Study http://www.statystyka1.medstat... (access: 2018.05.17).
24.
OECD (2017), Healthat a Glance 2017: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/health... (access: 2018.05.15).
25.
Kanecki K, Nitsch-Osuch A, Goryński P, Tarka P, Kutera A, Tyszko P. Behçet disease: a rare systemic vasculitis in Poland. Pol Arch Intern Med. 2017 Oct 31; 127(10): 652–6.
26.
Kanecki K, Nitsch-Osuch A, Gorynski P, Tarka P, Tyszko P. Hospital Morbidity Database for Epidemiological Studies on Churg-Strauss Syndrome. Adv Exp Med Biol. 2017; 980: 19–25.
27.
Kanecki K, Mikołajczyk M, Tyszko P. Kawasaki disease: increasing incidence in Poland. Scand J Rheumatol. 2016 Jan; 45(1): 82–3.
28.
Kanecki K, Nitsch-Osuch A, Gorynski P, Wierzba W, Tarka P, Tyszko P. Polyarteritis nodosa: decreasing incidence in Poland. Arch Med Sci DOI: https://doi.org/10.5114/aoms.2....
29.
Kanecki K, Nitsch-Osuch A, Gorynski P, Wierzba W, Tarka P, Tyszko P. Polyarteritis nodosa: decreasing incidence in Poland. Arch Med Sci DOI: https://doi.org/10.5114/aoms.2... Kanecki K, Życińska K, Moskalewicz B, Tyszko P. Granulomatosis with polyangiitis in Poland – epidemiological study. Reumatologia/Rheumatology. 2014 Jun 1; 2: 99–104.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.